
Celgene has revealed the US approval of Otezla (apremilast), confirming that the FDA awarded marketing authorisation for the treatment of …

Suzanne Morris speaks to Pharmafocus to discuss her life with Behçet’s disease, a rare condition characterised by the inflammation of …

Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEO

